MG
KZR

Michael Gelband’s Kezar Life Sciences KZR Stock Holding History

Michael Gelband’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,668
Closed -$329K – 1956
2022
Q4 		$329K Sell
4,668
-319
-6% -$23.7K ﹤0.01% 1322
2022
Q3 		$429K Sell
4,987
-17,286
-78% -$1.68M 0.01% 1420
2022
Q2 		$1.84M Buy
+22,273
New +$1.96M 0.02% 811
2022
Q1 		– Sell
-1,588
Closed -$265K – 2447
2021
Q4 		$265K Buy
+1,588
New +$179K ﹤0.01% 1712
2021
Q2 		– Sell
-1,767
Closed -$105K – 2593
2021
Q1 		$105K Buy
+1,767
New +$103K ﹤0.01% 1973

Other funds holding KZR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Michael Gelband's KZR Position: Q1 2023 in Review

Michael Gelband sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 4,668 shares — an estimated $329K sold.

Michael Gelband first reported a position in KZR in Q1 2021 and held it in 5 quarters. The position peaked at $1.84M in Q2 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Michael Gelband reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Michael Gelband sold 4,668 Kezar Life Sciences shares in Q1 2023, an estimated $329K.
  • Michael Gelband first reported a position in Kezar Life Sciences in Q1 2021 and held it in 5 quarters.
  • Michael Gelband's Kezar Life Sciences position peaked at $1.84M in Q2 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.